Exelixis, Inc. (EXEL)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Exelixis, Inc. (EXEL)
Go deeper and ask any question about EXEL
Company Performance
Current Price
as of Sep 13, 2024$26.46
P/E Ratio
22.66
Market Cap
$7.55B
Description
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Metrics
Overview
- HQAlameda, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerEXEL
- Price$26.46+0.57%
Trading Information
- Market Cap$7.55B
- Float97.42%
- Average Daily Volume (1m)1,473,725
- Average Daily Volume (3m)1,743,256
- EPS$1.19
Company
- Revenue$2.01B
- Rev Growth (1yr)35.61%
- Net Income$226.12M
- Gross Margin97.23%
- EBITDA Margin44.52%
- EBITDA$283.68M
- EV$5.80B
- EV/Revenue2.88
- P/E22.66
- P/S3.86
Documents
SEC Filings
Factset Street Account
Earnings Calls
Factset